TNGX — Tango Therapeutics Share Price
0.000.00%
Last trade - 00:00- $163.24m
- -$94.67m
- $42.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.82 | ||
| Price to Tang. Book | 0.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.31% | ||
| Return on Equity | -57.58% | ||
| Operating Margin | -346.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 37.04 | 24.86 | 36.53 | 42.07 | 29.24 | 25.03 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 21st, 2020
- Public Since
- September 3rd, 2020
- No. of Shareholders
- 17
- No. of Employees
- 155
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 108,107,890
- Address
- 201 Brookline Avenue, Suite 901, BOSTON, 02215
- Web
- https://www.tangotx.com/
- Phone
- +1 8573204900
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for TNGX
Tango Therapeutics Inc Annual Shareholders Meeting
Tango Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Tango Therapeutics Inc Earnings Release
Q3 2025 Tango Therapeutics Inc Earnings Release
Similar to TNGX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Tango Therapeutics share price?
As of Today at 23:35 UTC, shares in Tango Therapeutics are trading at $1.51. This share price information is delayed by 15 minutes.
How has the Tango Therapeutics share price performed this year?
Shares in Tango Therapeutics last closed at $1.51 and the price had moved by -80.11% over the past 365 days. In terms of relative price strength the Tango Therapeutics share price has underperformed the S&P500 Index by -82.06% over the past year.
What are the analyst and broker recommendations for Tango Therapeutics?
The overall consensus recommendation for Tango Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tango Therapeutics dividend yield?
Tango Therapeutics does not currently pay a dividend.
Does Tango Therapeutics pay a dividend?
Tango Therapeutics does not currently pay a dividend.
When does Tango Therapeutics next pay dividends?
Tango Therapeutics does not currently pay a dividend.
How do I buy Tango Therapeutics shares?
To buy shares in Tango Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tango Therapeutics?
As of the previous close price of $1.51, shares in Tango Therapeutics had a market capitalisation of $163.24m.
Where are Tango Therapeutics shares listed?
Here are the trading details for Tango Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TNGX
What kind of share is Tango Therapeutics?
Based on an overall assessment of its quality, value and momentum Tango Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tango Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Tango Therapeutics is $11.00. That is 628.48% above the last closing price of $1.51.
Analysts covering Tango Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.39 for the next financial year.
Find out moreWhat is the trend in the Tango Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tango Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -70.55%.
As of the last closing price of $1.51, shares in Tango Therapeutics were trading -69.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tango Therapeutics PE Ratio?
The Tango Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tango Therapeutics?
We do not have data on Tango Therapeutics' directors